TitleKaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines.
Publication TypeJournal Article
Year of Publication2008
AuthorsLopes, Eloisi C., Valls Ester, Figueroa Maria E., Mazur Alexander, Meng Fan-Guo, Chiosis Gabriela, Laird Peter W., Schreiber-Agus Nicole, Greally John M., Prokhortchouk Egor, and Melnick Ari
JournalCancer Res
Volume68
Issue18
Pagination7258-63
Date Published2008 Sep 15
ISSN1538-7445
KeywordsCell Cycle, Cell Death, Cell Line, Tumor, Colonic Neoplasms, Cyclin-Dependent Kinase Inhibitor p16, DNA Methylation, Gene Silencing, Genes, p16, Genes, Tumor Suppressor, HCT116 Cells, Humans, Promoter Regions, Genetic, Protein Binding, RNA, Small Interfering, Transcription Factors, Transfection
Abstract

<p>Aberrant CpG methylation of tumor suppressor gene regulatory elements is associated with transcriptional silencing and contributes to malignant transformation of different tissues. It is presumed that methylated DNA sequences recruit repressor machinery to actively shutdown gene expression. The Kaiso protein is a transcriptional repressor expressed in human and murine colorectal tumors that can bind to methylated clusters of CpG dinucleotides. We show here that Kaiso represses methylated tumor suppressor genes and can bind in a methylation-dependent manner to the CDKN2A in human colon cancer cell lines. The contribution of Kaiso to epigenetic silencing was underlined by the fact that Kaiso depletion induced tumor suppressor gene expression without affecting DNA methylation levels. As a consequence, colon cancer cells became susceptible to cell cycle arrest and cell death mediated by chemotherapy. The data suggest that Kaiso is a methylation-dependent "opportunistic" oncogene that silences tumor suppressor genes when they become hypermethylated. Because Kaiso inactivation sensitized colon cancer cell lines to chemotherapy, it is possible that therapeutic targeting of Kaiso could improve the efficacy of current treatment regimens.</p>

DOI10.1158/0008-5472.CAN-08-0344
Alternate JournalCancer Res
PubMed ID18794111
Grant ListR01 CA075090 / CA / NCI NIH HHS / United States
R01 CA118699 / CA / NCI NIH HHS / United States